Patent ID: 6809094
Filing Date: 2004-10-26
Classification: A61P,C07D

Abstract:
A compound of the formula whereinn=1; m=2; o=1; A=O, S or NR1; B=N or CR2; Q=N or CR3; D=N or CR4; E=N or CR5; R1 is H, a straight chain or branched (C1-C8)alkyl, C(&boxH;O)OR6, CH2R6, C(&boxH;O)NR6R7, C(&boxH;O)R6, or SO2R6; each R2, R3, R4 and R5 is independently selected from F, Cl, Br, I, nitro, cyano, CF3, â€”NR6R7, â€”NR6C(&boxH;O)R7, â€”NR6C(&boxH;O)NR7R8, â€”NR6C(&boxH;O)OR7, â€”NR8S(&boxH;O)2R7, â€”NR6S(&boxH;O)2NR7R6, â€”OR6, â€”OC(&boxH;O)R6, â€”OC(&boxH;O)OR6, â€”OC(&boxH;O)NR6R7, â€”OC(&boxH;O)SR6, â€”C(&boxH;O)OR6, â€”C(&boxH;O)R6, â€”C(&boxH;O)NR6R7, â€”SR6, â€”S(&boxH;O)R6, â€”S(&boxH;O)2R6, â€”S(&boxH;O)2NR6R7, and R6; each R6, R7, and R8 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl groups selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, quinuclidinyl and quinolizinyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl groups consisting of non-aromatic two-ringed cyclic groups, wherein at least one of the rings contains a heteroatom selected from O, S, or N, 5-11 membered heterobicycloalkenyl groups consisting of non-aromatic two-ringed cyclic groups, wherein at least one of the rings contains a heteroatom selected from O, S, or N and at least one endocyclic or exocyclic double bond, (C6-C11) aryl, and 5-12 membered heteroaryls selected from pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl, and azaindolyl; wherein each R6, R7, and R8 is optionally substituted with from one to six substituents, independently selected from F, Cl, Br, I, nitro, cyano, CF3, â€”NR9R10, â€”NR9C(&boxH;O)R10, â€”NR9C(&boxH;O)NR10R11, â€”NR9C(&boxH;O)OR10, â€”NR9S(&boxH;O)2R10, â€”NR9S(&boxH;O)2NR10R11, â€”OR9, â€”OC(&boxH;O)R9, â€”OC(&boxH;O)OR9, â€”OC(&boxH;O)NR9R10, â€”OC(&boxH;O)SR9, â€”C(&boxH;O)OR9, â€”C(&boxH;O)R9, â€”C(&boxH;O)NR9R10, â€”SR9, â€”S(&boxH;O)R9, â€”S(&boxH;O)2R9, â€”S(&boxH;O)2NR9NR10 and R9; each R9, R10 and R11 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocyloalkyl groups selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imdazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, quinuclidinyl and quinolizinyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl groups consisting of non-aromatic two-ringed cyclic groups, wherein at least one of the rings contains a heteroatom selected from O, S, or N, 5-11 membered heterobicycloalkenyl groups consisting of non-aromatic two-ringed cyclic groups, wherein at least one of the rings contains a heteroatom selected from O, S, or N and at least one endocyclic or exocyclic double bond, (C6-C11) aryl or 5-12 membered heteroaryls selected from pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl, and azaindolyl; wherein each R9, R10 and R11 is optionally substituted with from one to six substituents independently selected from F, Cl, Br, I nitro, cyano, CF3, â€”NR12R13, â€”NR12C(&boxH;C)R13, â€”NR12C(&boxH;O)NR13R14, â€”NR12C(&boxH;O)OR13, â€”NR12S(&boxH;O)2R13, â€”NR12S(&boxH;O)2NR13R14, â€”OR12, â€”OC(&boxH;O)R12, â€”OC(&boxH;O)OR12, â€”OC(&boxH;O)NR12R13, â€”OC(&boxH;O)SR12, â€”C(&boxH;O)OR12, â€”C(&boxH;O)R12, â€”C(&boxH;O)NR12R13, â€”SR12, S(&boxH;O)R12, â€”S(&boxH;O)2R12, â€”S(&boxH;O)2NR12R13 and R12; each R12, R13, and R14 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocyloalkyl groups selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imdazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, quinuclidinyl and quinolizinyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloaklyl groups consisting of non-aromatic two-ringed cyclic groups, wherein at least one of the rings contains a heteroatom selected from O, S, or N, 5-11 membered heterobicycloalkenyl groups consisting of non-aromatic two-ringed cyclic groups, wherein at least one of the rings contains a heteroatom selected from O, S, or N and at least one endocyclic or exocyclic double bond, (C6-C11) aryl and 5-12 membered heteroaryls selected from pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl, and azaindolyl; or R2 and R3, or R3 and R4, or R4 and R5, may form another 6-membered aromatic or heteroaromatic ring sharing B and Q, or Q and D, or D and E, respectively, and may be optionally substituted with from one to four substituents independently selected from the group of radicals set forth in the definition of R6, R7 and R8 above; or an enantiomeric, diastereomeric, or tautomeric isomer thereof, or a pharmaceutically acceptable salt of such compound or isomer.